Projects per year
Personal profile
Personal profile
Dr. Bulent Ozpolat earned his PhD in Immunology from the University of Texas MD Anderson Cancer Center, Graduate School of Biomedical Sciences (GSBS), under the guidance of Lawrence Lachman. Prior to this, he obtained his M.D. degree from Dokuz Eylul University, Izmir, Turkey. His doctoral work concentrated on DNA-vaccines against HIV, Helicobacter Pylori, and HER2+ breast cancer, employing immunoliposomes with adjuvants and interleukins. Following his PhD, he underwent postdoctoral training at MD Anderson and later served 15 years as faculty in Experimental Therapeutics.
With over 135 peer-reviewed publications, he has received numerous research awards and holds patents. Supported by funding from NIH/NCI, US Congressionally Directed Medical Research & Department of Defense, Susan Komen, NHARP, CPRIT, and Blanton-Davis Ovarian Cancer Research Program, he also contributes as an editor and board member for scientific journals.
Research interests
Dr. Ozpolat's research emphasizes developing targeted cancer therapies like small molecule inhibitors and microRNA-based nanotherapeutics, using tumor-targeting nanocarriers for delivering various agents. He explores novel molecular targets, non-coding RNAs, and immune therapies for solid cancers, including breast, pancreatic, lung, ovarian, and brain tumors. Notably, his work involves nanocarriers targeting survival pathways like eEF2-kinase (eEF2K), FOXM1, KRAS, and immunosuppressive pathways like PDL1 signaling.
Education/Academic qualification
Immunology, PhD, Development of a protective vaccine against Helicobacter pylori, University of Texas at Houston Graduate School of Biomedical Sciences
Jan 14 1994 → Dec 14 1999
Award Date: Dec 14 1999
External positions
Professor of Nanomedicine in Medicine, Weill-Cornell Medical College
Nov 1 2023 → …
Research Area Keywords
- Cancer
- Nanomedicine
- Precision Medicine
Free-text keywords
- Cancer biology
- Drug development
- Nano-therapeutics targeting
- Nanotechnology
- Gene Therapy
- RNA therapeutics
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
-
miR-155 Targeted Therapeutics for Precision Medicine in Lung Cancer
8/1/22 → 7/31/23
Project: Federal Funding Agencies
-
PIM3 Kinase: A Promising Novel Target in Solid Cancers
Atalay, P. & Ozpolat, B., Feb 2024, In: Cancers. 16, 3, 535.Research output: Contribution to journal › Review article › peer-review
Open Access -
SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer
Kara, G. & Ozpolat, B., Mar 2024, In: Biomedical Microdevices. 26, 1, 16.Research output: Contribution to journal › Review article › peer-review
-
Author Correction: Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer
Rodriguez-Aguayo, C., del C Monroig, P., Redis, R. S., Bayraktar, E., Almeida, M. I., Ivan, C., Fuentes-Mattei, E., Rashed, M. H., Chavez-Reyes, A., Ozpolat, B., Mitra, R., Sood, A. K., Calin, G. A. & Lopez-Berestein, G., Nov 8 2023, In: Cell Discovery. 9, 1, p. 111 111.Research output: Contribution to journal › Article › peer-review
Open Access -
Flavopiridol Suppresses Cell Proliferation and Migration and Induces Apoptotic Cell Death by Inhibiting Oncogenic FOXM1 Signaling in IDH Wild-Type and IDH-Mutant GBM Cells
Guler, A., Hamurcu, Z., Ulutabanca, H., Cınar, V., Nurdinov, N., Erdem, S. & Ozpolat, B., Sep 7 2023, (E-pub ahead of print) In: Molecular Neurobiology. 61, 2, p. 1061-1079 19 p.Research output: Contribution to journal › Article › peer-review
-
Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
Dilmac, S. & Ozpolat, B., Jul 16 2023, In: Cancers. 15, 14, 3642.Research output: Contribution to journal › Review article › peer-review
Open Access2 Scopus citations